The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Cardiovascular Effects of Atomoxetine in Children, Adolescents, and Adults
Abstract
Background Atomoxetine is a highly specific presynaptic inhibitor of the noradrenaline (norepinephrine) transporter that was recently approved in the US for the treatment of patients with attention-deficit/hyperactivity disorder (ADHD). Adverse effects on the cardiovascular system, including abnormalities in heart rate, blood pressure, or cardiac rhythm have been associated with several noradrenergic medications.Objective To further elucidate the magnitude and impact of blood pressure and pulse elevations in patients taking atomoxetine.Study design Short-term cardiovascular safety in children, adolescents, and adults with ADHD was assessed in five randomised, double-blind trials (duration up to 10 weeks) with atomoxetine (n = 612) or placebo (n = 474). Long-term cardiovascular safety in children and adolescents (n = 169) was assessed in patients who entered an open-label extension or a blinded continuation following short-term treatment.Methods Adverse events, blood pressure, sitting pulse, and electrocardiograms (ECGs) were collected throughout the trials. QT intervals were corrected for heart rate by a data-specific correction factor (QTcD; derived from baseline ECGs) as well as standard methods.Results Atomoxetine treatment was associated with small but statistically significant increases in mean systolic blood pressure in adults and diastolic blood pressure in children and adolescents. Mean pulse rate increased for all atomoxetine treatment groups. The increases in blood pressure and pulse tended to occur early in therapy, stabilised, and returned toward baseline upon drug discontinuation. There was no significant difference between atomoxetine and placebo treatment groups in change in QTcD interval for all study populations. Palpitations in the adult patient population were the only significant cardiovascular adverse event (p = 0.037) occurring more frequently in the atomoxetine treatment group (3.7%) than in the placebo group (0.8%). Discontinuations due to cardiovascular-related events were very uncommon in the adult group, and did not occur in the child/adolescent group.Conclusion While atomoxetine has noradrenergic activity, increases in pulse and blood pressure were small and of little, if any, clinical significance. Atomoxetine was not associated with QT interval prolongation. Cardiovascular effects of atomoxetine were minimal, and atomoxetine was well tolerated in short- and long-term studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For categorically measured hypertension, controlled trial data are available for atomoxetine and indicate that elevations above the 95th percentile are seen in 6.8% of patients (systolic) and 2.8% (diastolic), in comparison to 3 and 0.5%, respectively, of patients treated with placebo [150].”
From European guidelines on managing adverse effects of medication for ADHD (2011) · cites this paper as [150]
In the citing paper
“All stimulant medications and atomoxetine are reported to cause elevations in blood pressure [150].”
From European guidelines on managing adverse effects of medication for ADHD (2011) · cites this paper as [150]
In the citing paper
“The averaging of data in clinical studies can hide a small proportion where the increment is larger; indeed up to 50 beats/min in rare cases [150].”
From European guidelines on managing adverse effects of medication for ADHD (2011) · cites this paper as [150]
In the citing paper
“Stimulant and non-stimulant medications are recognised to cause a small increase in heart rate averaging 1–2 beats per minute [146, 150].”
From European guidelines on managing adverse effects of medication for ADHD (2011) · cites this paper as [150]
In the citing paper
“While the average increases range from 1–4 mmHg systolic and 1–2 mmHg diastolic, this small average change includes patients where the rise in blood pressure is more significant, and there are also data showing increases above the 95th centile in individuals taking ADHD medications.”
From European guidelines on managing adverse effects of medication for ADHD (2011) · cites this paper as [150]
In the citing paper
“While the average increases range from 1–4 mmHg systolic and 1–2 mmHg diastolic, this small average change includes patients where the rise in blood pressure is more significant, and there are also data showing increases above the 95th centile in individuals taking ADHD medications.”
From European guidelines on managing adverse effects of medication for ADHD (2011) · cites this paper as [150]
Citations
Cites
Extending Indications for Long-Term Pharmacotherapy: Opportunities and Challenges
Kane, J. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.1 · Cited by 989
Haller, C. A., & Benowitz, N. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432502 · Cited by 956
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
Self-citationMichelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Self-citationMichelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599
Self-citationRate-corrected QT interval: Techniques and limitations
Funck‐Brentano, C., & Jaillon, P. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90035-b · Cited by 401
BIEDERMAN, J., FARAONE, S. V., MICK, E., WILLIAMSON, S., WILENS, T. E., SPENCER, T. J., WEBER, W., JETTON, J., KRAUS, I., PERT, J., et al. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199908000-00012 · Cited by 364
Spencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333
Self-citationThase, M. E. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1002 · Cited by 331
Acute Tolerance to Subjective but not Cardiovascular Effects of d-Amphetamine in Normal, Healthy Men
Brauer, L. H., AMBRE, J. J., & de Wit, H. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199602000-00012 · Cited by 64
Cited by
Sorted by citations
Items 101–191 of 191
Atomoxetine-induced electrocardiogram changes
Rajesh, A. S., Bates, G. D. L., & Wright, J. G. C. (2006) · Archives of Disease in Childhood · doi:10.1136/adc.2005.087460 · Cited by 16
Hennessy, S., Schelleman, H., Daniel, G. W., Bilker, W. B., Kimmel, S. E., Guevara, J. P., Cziraky, M. J., & Strom, B. L. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1992 · Cited by 15
Screening for drugs to reduce aggression in zebrafish
Norton, W. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.10.023 · Cited by 15
Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers
Loghin, C., Haber, H. E., Beasley, C. M., Kothare, P. A., Kauffman, L., April, J., Jin, L., Allen, A. J., & Mitchell, M. I. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04382.x · Cited by 15
Upadhyaya, H., Tanaka, Y., Lipsius, S., Kryzhanovskaya, L., Lane, J. R., Escobar, R., Trzepacz, P., & Allen, A. (2015) · Postgraduate medicine · doi:10.1080/00325481.2015.1083394 · Cited by 12
Atomoxetine-induced life-threatening long QT syndrome
Štuhec, M., & Švab, V. (2013) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-013-0925-y · Cited by 14
Serotonin Syndrome After a Massive Overdose of Controlled-Release Paroxetine
Muzyk, A. J., Jakel, R. J., & Preudʼhomme, X. (2010) · Psychosomatics · doi:10.1016/s0033-3182(10)70727-1 · Cited by 14
Purper‐Ouakil, D., Fourneret, P., Wohl, M., & Rénéric, J.-P. (2005) · L Encéphale · doi:10.1016/s0013-7006(05)82399-1 · Cited by 14
Li, W. Y., Strang, S. E., Brown, D. R., Smith, R., Silcox, D. L., Li, S.-G., Baldridge, B. R., Nesselroade, K. P., & Randall, D. C. (2009) · Autonomic Neuroscience · doi:10.1016/j.autneu.2009.11.003 · Cited by 13
Sert, A., Gökçen, C., Aypar, E., & Odabaş, D. (2011) · Cardiology in the Young · doi:10.1017/s1047951111001211 · Cited by 12
Current nonstimulant medications for adults with attention-deficit/hyperactivity disorder
Brancati, G. E., Magnesa, A., Acierno, D., Carli, M., Rosa, U. D., Froli, A., Gemignani, S., Ventura, L., Weiss, F., & Perugi, G. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2370346 · Cited by 16
Pharmacotherapy of ADHD in adults
Prince, J. B., Morrison, N. R., & Wilens, T. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139035491.023 · Cited by 11
Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder
Robinson, C. L., Parker, K., Kataria, S., Downs, E., Supra, R., Kaye, A. D., Viswanath, O., & Urits, I. (2022) · Health Psychology Research · doi:10.52965/001c.38360 · Cited by 15
Cardiovascular Effects of Drugs Used to Treat Attention-Deficit/Hyperactivity Disorder
Fay, T. B., & Alpert, M. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000233 · Cited by 11
Monoaminergic‐based Pharmacotherapy for Depression
Papakostas, G. I., & D, M. F. M. (2005) · Wiley eBooks · doi:10.1002/9783527619672.ch6 · Cited by 11
Jin, L., Xu, W., Krefetz, D. G., Gruener, D., Kielbasa, W., Tauscher‐Wisniewski, S., & Allen, A. J. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0016 · Cited by 10
Off-label use of atomoxetine in adults: is it safe?
Dadashova, R., & Silverstone, P. H. (2012) · Mental Illness · doi:10.4081/mi.2012.e19 · Cited by 10
Li, Y., Liu, W., Zhu, Y., Liu, X., & Winterstein, A. G. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000759 · Cited by 10
Uzark, K. C., Webb, C. L., Vetter, V. L., Elia, J., Erickson, C., Berger, S., & Blum, N. J. (2011) · Cited by 9
Kinoshita, S., Kakuda, W., Yamada, N., Momosaki, R., Okuma, R., Watanabe, S., & Abo, M. (2015) · Acta Neurologica Belgica · doi:10.1007/s13760-015-0503-3 · Cited by 8
Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
McDonagh, M. S., & Peterson, K. (2011) · Cited by 7
Imagawa, H., Nagar, S. P., Montgomery, W. S., Nakamura, T., Sato, M., & Davis, K. L. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s150261 · Cited by 7
Blood pressure in children with attention deficit/hyperactivity disorder
Grisaru, S., Yue, M., Samuel, S. M., Chaput, K. H., & Hamiwka, L. A. (2018) · Paediatrics & Child Health · doi:10.1093/pch/pxx207 · Cited by 7
Patel, H., Simpson, A., Palevoda, G., & Hale, G. M. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13260 · Cited by 7
Tajdini, M., Aminorroaya, A., Tavolinejad, H., Tofighi, S., Jalali, A., Sadeghian, S., Vasheghani‐Farahani, A., Yadangi, S., Shahmansouri, N., Akhondzadeh, S., et al. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100789 · Cited by 7
Kardiovaskulær risikovurdering ved bruk av AD/HD-medikamenter hos barn
Berg, A., Bråtane, E., Odland, H. H., Brudvik, C. E., Rosland, B., & Hirth, A. (2014) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.13.0565 · Cited by 8
A new paradigm for developing drugs in children: atomoxetine as a model
Prasad, S. (2005) · Archives of Disease in Childhood · doi:10.1136/adc.2004.059378 · Cited by 7
Kandukuru, A., Sharma, P., Gupta, S. V., Nkembo, A. T., & Sutariya, V. B. (2024) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2024-0128 · Cited by 6
Bady, Z. A. M., Mohammed, H. E., Aboeldahab, H. A., Samir, M., Aissani, M. S., & Hussein, A. A. R. M. (2024) · Sleep And Breathing · doi:10.1007/s11325-024-03227-6 · Cited by 6
Suzuki, Y., Tajiri, M., Sugimoto, A., Orime, N., Hayashi, T., Egawa, J., Sugai, T., Inoue, Y., & Someya, T. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000630 · Cited by 6
The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite
Todor, I., Popa, A., Neag, M., Muntean, D., Bocsan, C., Buzoianu, A., Vlase, L., Gheldiu, A., Chira, R., & Briciu, C. (2015) · Clujul Medical · doi:10.15386/cjmed-488 · Cited by 8
Treatment of Psychiatric Comorbidities in Tourette Syndromes
Cardona, F., & Rizzo, R. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199796267.003.0025 · Cited by 6
Sohn, M., Talbert, J., Moga, D. C., & Blumenschein, K. (2016) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-016-0198-1 · Cited by 6
Sieluk, J., Palasik, B. N., dosReis, S., & Doshi, P. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4164 · Cited by 6
Yamaguchi, I., & Hanevold, C. D. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0968-1 · Cited by 6
Turgay, A. (2006) · Therapy · doi:10.2217/14750708.3.1.19 · Cited by 6
Quality Improvement, Subcommittee on Attention-Deficit/Hyperactivity Disorder
Feldman, H. M., Pierce, K., Wolraich, M. L., Brown, R. T., Amler, R. W., Freeman, W., & Perrin, J. M. (2007) · Cited by 6
Uzark, K. C., Webb, C. L., Vetter, V. L., Elia, J., Erickson, C., Berger, S., & Blum, N. J. (2008) · Cited by 6
(2005) · CRC Press eBooks · doi:10.1201/b14455-6 · Cited by 6
Attention‐Deficit Hyperactivity Disorder
Rube, D. M., & Kaur, T. (2012) · Wiley eBooks · doi:10.1002/9781119962229.ch10 · Cited by 6
Graham, J. S., Seth, S., & Coghill, D. (2007) · Medicine · doi:10.1016/j.mpmed.2007.01.002 · Cited by 5
Potential Effect of Pharmacotherapy on Sympathetic Arousal in Autism
Bujnakova, I., Ondrejka, I., Mestanik, M., Flešková, D., Sekaninova, N., Farský, I., & Tonhajzerová, I. (2017) · Acta Medica Martiniana · doi:10.1515/acm-2017-0013 · Cited by 6
Attention Deficit Hyperactivity Disorder
Marco, P., Maddalena, M., Bertella, S., Gatti, E., & Nobile, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00164-x · Cited by 5
Effects of atomoxetine on heart rhythm in children and adolescents
Tanıdır, İ. C., Tanıdır, C., Öztürk, E., Bahalı, K., Güneş, H., Ergül, Y., Üneri, Ö. Ş., Akdeniz, C., & Tuzcu, V. (2015) · Pediatrics International · doi:10.1111/ped.12726 · Cited by 4
Adult Attention Deficit Hyperactivity Disorder (ADHD) in ASD
Salerno, L., & Kooij, J. J. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-26276-1_11 · Cited by 4
Nery, E. S. M., Bangs, M. E., Liu, P., AHL, J. S. B., & David, P. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0110 · Cited by 4
Safety and Tolerability of Medications for ADHD
Clavenna, A., & Bonati, M. R. (2015) · Springer eBooks · doi:10.1007/978-3-319-24741-0_12 · Cited by 3
Cismaru, G. L., & Lupu, V. (2021) · Journal of Mind and Medical Sciences · doi:10.22543/7674.82.p209214 · Cited by 3
Managing Adverse Reactions to Psychotropic Medications
Bebarta, V. S., Kostic, M. A., & Gonzalez, M. G. (2005) · Pediatric Annals · doi:10.3928/0090-4481-20051201-10 · Cited by 3
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg005 · Cited by 3
Kardiovaskuläres Risiko bei ADHS-Behandlung
Wenzel‐Seifert, K., & Haen, E. (2012) · NeuroTransmitter · doi:10.1007/s15016-012-0369-z · Cited by 2
Psychopharmacological Management of Children and Adolescents
Lorberg, B. A., & Prince, J. B. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-1927-7.00035-2 · Cited by 2
Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder across the Life Span
Prince, J. B., Spencer, T. J., Wilens, T. E., & Biederman, J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04743-2.50051-2 · Cited by 2
TDAH CON TRASTORNOS DE ANSIEDAD
Tannock, R. (2010) · Elsevier eBooks · doi:10.1016/b978-84-458-2021-6.00008-7 · Cited by 2
Studying aggression in zebrafish
Norton, W., & Winberg, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817528-6.00027-9 · Cited by 2
Go, S., Takahashi, R., Suzuki, S., Kasuga, A., Morıchı, S., Ishida, Y., Yamanaka, G., Kashiwagi, Y., & Kawashima, H. (2020) · Clinical Autonomic Research · doi:10.1007/s10286-020-00701-5 · Cited by 2
Atomoxetinbehandlung von Kindern und Jugendlichen mit ADHS
Sevecke, K., Dittmann, R., Lehmkuhl, G., & Döpfner, M. (2005) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-005-1153-y · Cited by 2
Üneri, Ö. Ş., Çöpür, M., Tanıdır, C., Güneş, H., & Erdoğan, A. (2012) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.5350/dajpn2013260102 · Cited by 1
Risk of cardiovascular disease associated with ADHD treatment
Holt, A., Lamberts, M., Elberling, H., & Hansen, H. G. (2025) · Ugeskrift for Læger · doi:10.61409/v11240840 · Cited by 1
Epigenetics in Child Psychiatry
Elia, J., Kingsley, R. S., Yost, O., Bongiorno, C., Bernacki, C. G., Ambrosini, A. P., Okuyama, M., & Hakonarson, H. H. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-417114-5.00020-6 · Cited by 1
Aufmerksamkeitsdefizit-Hyperaktivitäts-Störung
Hulpke‐Wette, M., & Paul, T. (2010) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-010-2219-z · Cited by 1
Taracena, M. T. D. L., & Rada, F. M. (2007) · Psiquiatría Biológica · doi:10.1016/s1134-5934(07)73255-4 · Cited by 1
Gaillez, C., Sorbara, F., & Perrin, E. (2007) · L Encéphale · doi:10.1016/s0013-7006(07)92063-1 · Cited by 1
What does it mean? Looking beyond group differences in clinical research
Coghill, D. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-011-0222-0 · Cited by 1
InforMatrix for attention deficit hyperactivity disorder
Janknegt, R., Faber, A., Pereira, R. R., & Kalverdijk, L. J. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902765769 · Cited by 1
The use of nonstimulant drugs in the treatment of adult ADHD
Wim, J., Verbeeck, C., & Tuinier, S. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511780752.019
Gevensleben, H. (2012) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1440
The alpha2C-adrenoceptor as a neuropsychiatric drug tar-get - PET studies in human subjects
Lehto, J. (2015) · UTUPub (University of Turku)
Adverse Effects of Psychostimulant Medications Working Group
Cooper, W. O., Habel, L. A., Chan, K. A., & Mosholder, A. D. (2011)
Šnircová, E., Kulhan, T., Nosalova, G., & Ondrejka, I. (2012) · Acta Medica Martiniana · doi:10.2478/v10201-011-0039-z
Does the prescribing context for ADHD medications suggest cognitive enhancement motivation?
Bilder, S. M. (2012) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t3w37v7b
Sohn, M. (2014) · UKnowledge (University of Kentucky)
ATOMOKSETÝN: ÇOCUK VE ERGENLERDEKÝ ETKÝNLÝÐÝ VE YAN ETKÝLERÝ
Öç, Ö. Y., Karakaya, İ., & Memýk, N. Ç. (2007)
Graham, J. M., Seth, S., & Coghill, D. (2007)
Central nervous system stimulants and drugs that suppress appetite
Sequeira, R. P. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00001-5
Proto, D. A. (2012) · Louisiana State University · doi:10.31390/gradschool_dissertations.654
TRATAMIENTO FARMACOLÓGICO DEL TDAH Y LAS COMORBILIDADES
Prince, J. B., & Wilens, T. E. (2010) · Elsevier eBooks · doi:10.1016/b978-84-458-2021-6.00019-1
Atomoxetine in the pharmacotherapy of hyperkinetic syndrome
Środowiskowe Centrum Zdrowia Psychicznego dla Dzieci i Młodzieży – Warszawa Bielany, E. U. S. Z. O. O., & Wiśniewski, A. (2020) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2020.0009 · Cited by 1
Role of TASK-1/3 Channels at the Hypoglossal Motor Nucleus in Modulating Motor Output
Gurges, P. (2019) · TSpace (University of Toronto)
Das, B., Rawat, V. S., Ramasubbu, S. K., Agnihotri, A., & Kumar, B. (2021) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2021.101456
(2012) · Wiley eBooks · doi:10.1002/9781119977452.refs
Psychotropic agents and torsades de pointes
Funk, M. C., & Beach, S. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821446-6.00001-8
Current awareness: Pharmacoepidemiology and drug safety
(2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.915
Treatment of Psychiatric Comorbidities in Tourette Syndrome
Cardona, F., & Rizzo, R. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780197543214.003.0027
No stimulant? No Problem: Analyzing Black Market Sales of Atomoxetine on StreetRxPreprint
Roe, S. A., DeSalve, D. S., & Piper, B. J. (2022) · medRxiv · doi:10.1101/2022.12.19.22283638
Norepinephrine transporter inhibitors in autonomic disorders
Shibao, C. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85492-4.00008-9
Medications for Children and Adolescents with ADHD
Matson, J. L. (2023) · Autism and child psychopathology series · doi:10.1007/978-3-031-41709-2_26
Prescribing in Children and Adolescents
(2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg005.pub2
Choo, Y., Segal, A. E., Carnahan, R. M., Chalkley, N. H., Potter, R., Dolan, K. A., Nickl‐Jockschat, T., & Wessel, J. R. (2026) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2026.05.014
Seasonality and changes in ADHD medication sales to pharmacies in Poland from 2018 to 2023
Rzeszutek, M., & Wolańczyk, T. (2026) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.905
Metadata
- Authors
- Wernicke, J. F., Faries, D., Girod, D., Brown, J. W., Gao, H., Kelsey, D., Quintana, H., Lipetz, R., Michelson, D., & Heiligenstein, J.
- Affiliations
- Eli Lilly (United States) (US)
- Louisiana State University Health Sciences Center New Orleans (US)
- Encompass Health (United States) (US)
- Corresponding author
- Wernicke, Joachim F
- Venue
- Drug Safety
- Published
- 2003
- Volume
- 26
- Issue
- 10
- Pages
- 729-740
- ISSN
- 0114-5916 (ISSN-L)
- OpenAlex
- W2094270069
- Cited by
- 191
- References
- 12
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 8 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 5 · 2017: 8 · 2016: 3 · 2015: 13 · 2014: 8 · 2013: 9 · 2012: 13
- FWCI
- 6.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- atomoxetine, cardiovascular safety, attention deficit hyperactivity disorder, blood pressure, pulse rate, QT interval, palpitations, cardiovascular adverse events, children and adolescents, adults
- MeSH terms
- Atomoxetine Hydrochloride, Adolescent, Adult, Attention Deficit Disorder with Hyperactivity, Blood Pressure, Child, Double-Blind Method, Electrocardiography, Female, Heart Conduction System, Hemodynamics, Humans, Male, Propylamines, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
